bis-(2,2-dichloro-1,1-difluoro-ethyl) ether | 38595-65-2

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: bis-(2,2-dichloro-1,1-difluoro-ethyl) ether
• 英文别名: Bis-(2,2-dichlor-1,1-difluoraethyl)-aether；2,2-Dichloro-1-(2,2-dichloro-1,1-difluoroethoxy)-1,1-difluoroethane
• CAS: 38595-65-2
• 化学式: C₄H₂Cl₄F₄O
• 分子量: 283.865
• InChiKey: LLSWESFIHBBZME-UHFFFAOYSA-N

物化性质

• 沸点：
  199.6±35.0 °C(Predicted)
• 密度：
  1.678±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  二氯乙酸 在 sulfur tetrafluoride 作用下， 反应 3.0h， 生成 二氯三氟乙烷 、 bis-(2,2-dichloro-1,1-difluoro-ethyl) ether
  参考文献：
  名称：

  Dmowski,W.; Kolinski,R., Roczniki Chemii, 1973, vol. 47, p. 1211 - 1221

  摘要：

  DOI：

文献信息

• [EN] COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF<br/>[FR] COMPOSÉS COMPRENANT UN LIEUR CLIVABLE ET LEURS UTILISATIONS
  申请人：INTOCELL INC

  公开号：WO2019008441A1

  公开（公告）日：2019-01-10

  Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active agent (for example, a drug, a toxin, a ligand, a probe for detection, etc.) having a specific function or activity, a SO2 functional group which is capable of selectively releasing the active agent, and a functional group which triggers a chemical reaction, a physicochemical reaction and/or a biological reaction by external stimulation, and may further include a ligand (for example, oligopeptide, polypeptide, antibody, etc.) having binding specificity for a desired target receptor.

  提供了一种包括可切割连接物的化合物，其用途，以及用于制备该化合物的中间体化合物，更具体地，本发明的包括可切割连接物的化合物可能包括具有特定功能或活性的活性剂（例如，药物，毒素，配体，用于检测的探针等），能够选择性释放活性剂的SO2官能团，以及通过外部刺激触发化学反应，物理化学反应和/或生物反应的官能团，并且还可以包括具有与所需靶受体结合特异性的配体（例如，寡肽，多肽，抗体等）。
• Nuclear receptor binding agents
  申请人：Dalton James T.

  公开号：US20090030036A1

  公开（公告）日：2009-01-29

  The present invention relates to a novel class of nuclear receptor binding agents (NRBAs). The NRBAs are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, inflammatory diseases, oxidative stress related disorders such as Parkinson's and stroke, neurological disorders, ophthalamic disorders, cardiovascular disease, and obesity.

  本发明涉及一种新型的核受体结合剂（NRBAs）。这些NRBAs适用于预防和/或治疗各种疾病和病症，包括预防和治疗癌症（如前列腺癌和乳腺癌）、骨质疏松症、激素相关疾病、炎症性疾病、氧化应激相关疾病（如帕金森病和中风）、神经系统疾病、眼科疾病、心血管疾病和肥胖症。
• NUCLEAR RECEPTOR BINDING AGENTS
  申请人：DALTON James T.

  公开号：US20120157539A1

  公开（公告）日：2012-06-21

  The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity.

  本发明涉及一种新型选择性雌激素受体调节剂（SERMs）类。这些SERM化合物适用于预防和/或治疗各种疾病和病况，包括预防和治疗癌症，如前列腺癌和乳腺癌，骨质疏松症，激素相关疾病，潮热或血管运动症状，神经疾病，心血管疾病和肥胖症。
• ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF
  申请人：DALTON James T.

  公开号：US20120077845A1

  公开（公告）日：2012-03-29

  The present invention relates to methods for reducing testosterone levels by reduction of luteinizing hormone (LH) or independent of LH levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate cancer, and castration-resistant prostate cancer (CRPC) and palliative treatment of prostate cancer, advanced prostate cancer and castration-resistant prostate cancer (CRPC). The compounds of this invention suppress free or total testosterone levels to castrate levels which may be used to treat prostate cancer, advanced prostate cancer, and CRPC without causing bone loss, decreased bone mineral density, increased risk of bone fractures, increased body fat, hot flashes and/or gynecomastia.

  本发明涉及一种通过降低雄激素水平来减少雄性受试者中黄体生成素（LH）或独立于LH水平的方法，以及治疗、抑制、减少发病率、减轻病情或抑制前列腺癌、晚期前列腺癌和去势抵抗性前列腺癌（CRPC）以及前列腺癌、晚期前列腺癌和去势抵抗性前列腺癌（CRPC）的姑息治疗的方法。本发明的化合物可将游离或总睾酮水平抑制到去势水平，可用于治疗前列腺癌、晚期前列腺癌和CRPC，而不会引起骨质流失、骨密度降低、骨折风险增加、体脂增加、潮热和/或乳腺增生。
• ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS
  申请人：DALTON James T.

  公开号：US20130116277A1

  公开（公告）日：2013-05-09

  The present invention relates to a novel class of AKR1C3 inhibitors, to compositions containing them, to methods for their preparation, and to methods of use thereof. The AKR1C3 inhibitors may be useful in the treatment of, for example, prostate cancer, benign prostate hyperplasia (BPH), lung cancer, acne, seborrhea, hirsuitism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, uterine cancer, uterine fibroids, endometriosis, myeloma and leiomyoma.

  本发明涉及一种新型AKR1C3抑制剂类，包含其组成物，其制备方法以及使用方法。这些AKR1C3抑制剂可能在治疗前列腺癌、良性前列腺增生症（BPH）、肺癌、痤疮、皮脂溢出、多毛症、脱发、斑秃、性早熟、肾上腺增生、多囊卵巢综合症、乳腺癌、子宫癌、子宫肌瘤、子宫内膜异位症、骨髓瘤和平滑肌瘤的治疗中有用。